Back to results
US 2003/0118598 A1Published application
Clostridial toxin pharmaceutical compositions
AssigneeAllergan, Inc.
InventorTerrence J. Hunt
Life of this patent
Estimating the term…
Abstract
A botulinum toxin pharmaceutical formulation free of animal derived proteins, comprising a botulinum toxin and a recombinant albumin, suitable for therapeutic administration to a human patient, and methods for treating patients with various diseases and afflictions with the formulation.
Claims19
A pharmaceutical composition, comprising:
- (a) a botulinum toxin, and;
- (b) a recombinant stabilizer.
A pharmaceutical composition, comprising:
- (a) a botulinum toxin type A, and;
- (b) a recombinant albumin.
A pharmaceutical composition, comprising
- (a) a botulinum toxin;
- (b) a non-oxidizing amino acid derivative, and;
- (c) zinc.
A pharmaceutical composition, comprising
- (a) a botulinum toxin
- (b) a primary stabilizer, and;
- (c) and a secondary stabilizer, wherein the secondary stabilizer is a metal.
A pharmaceutical composition, comprising:
- (a) a botulinum toxin, and;
- (b) rHSA, wherein pharmaceutical composition exhibits an enhanced antimicrobial activity.
A pharmaceutical composition, comprising:
- (a) a botulinum toxin, and;
- (b) rHSA, wherein the pharmaceutical composition exhibits an enhanced potency.
A pharmaceutical composition, comprising
- (a) a botulinum toxin;
- (b) NAT;
- (c) zinc;
- (d) caprylate
- (e) rHSA, and
- (f) P80, wherein the pharmaceutical composition exhibits both an enhanced antimicrobial activity and an enhanced potency.
3 more elements
Dependencies are inferred from the claim text.